Restoring Balance: Current and Emerging Management of MGD (CME Symposium)

Activity Description

Meibomian gland dysfunction is characterized by inflammation in the meibomian glands in the eyelids, which leads to poor tear film quality and exacerbated evaporation of the tear film from the ocular surface. Meibomian gland dysfunction is a major driver of dry eye disease, yet diagnosis is often delayed, leading to delayed treatment and undesirable patient outcomes. In this educational activity, experts will present real-world cases that review best practices in the early diagnosis of meibomian gland dysfunction, review current treatment strategies, an discuss emerging treatments for meibomian gland dysfunction.

Target Audience

This educational activity is intended for ophthalmologists.

Learning Objectives

After completing this activity, participants will be better able to:

  • Describe the pathophysiology of meibomian gland dysfunction–associated dry eye disease
  • Implement best practices for diagnosing patients with meibomian gland dysfunction
  • Evaluate clinical trial data for agents under development for the treatment of meibomian gland dysfunction–associated dry eye disease
  • Design evidence-based treatment plans for persons with meibomian gland dysfunction–associated dry eye disease
Course summary
Available credit: 
  • 1.50 AMA PRA Category 1 Credit™
  • 1.50 Participation
Course opens: 
10/01/2022
Course expires: 
12/30/2022
Cost:
$0.00

Welcome, Introductions, and Pretest—Eric D. Donnenfeld, MD

Prevalence and Epidemiology of MGD—Eric D. Donnenfeld, MD

Overview of MGD Pathophysiology—Kenneth A. Beckman, MD, FACS

Diagnosis of MGD—Alice T. Epitropoulos, MD, FACS

Current Treatments for MGD—Marguerite B. McDonald, MD, FACS

Emerging Treatments for MGD (Round Robin)

Case 1: MGD in Glaucoma—Alice T. Epitropoulos, MD, FACS

Case 2: Contact Lens Intolerance, MGD, Seeking LASIK—Marguerite B. McDonald, MD, FACS

Case 3: Presurgical Management of MGD/DED—Kenneth A. Beckman, MD, FACS

Posttest

Q&A

Faculty

Eric D. Donnenfeld, MD (Chair)
Clinical Professor of Ophthalmology
New York University Langone Medical Center
New York, New York
Founding Partner
Ophthalmic Consultants of Long Island and Connecticut
Garden City, New York
Kenneth A. Beckman, MD, FACS
Clinical Assistant Professor of Ophthalmology
Ohio State University
Columbus, Ohio
Director of Corneal Surgery
Comprehensive Eye Care of Central Ohio
Westerville, Ohio
Alice T. Epitropoulos, MD
Clinical Assistant Professor of Ophthalmology
Ohio State University
Ophthalmic Surgeons & Consultants of Ohio
Eye Center of Columbus
Director, Dry Eye Center of Excellence
Columbus, Ohio
Marguerite B. McDonald, MD, FACS
Clinical Professor of Ophthalmology
New York University Langone Medical Center
New York, New York
Clinical Professor of Ophthalmology
Tulane University Health Sciences Center
New Orleans, Louisiana
Ophthalmic Consultants of Long Island
Oceanside, New York

Disclosure Policy

MedEdicus adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CME activity, including faculty, planners, reviewers, or others, are required to disclose all financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been identified and mitigated by MedEdicus prior to the commencement of the activity.

Faculty

Kenneth A. Beckman, MD, is a consultant for Alcon, Allergan, Avellino, Bausch & Lomb Incorporated, Bio-Tissue, Bruder Healthcare, Dompé US, Inc, EyePoint Pharmaceuticals, Glaukos Corporation, Glint Pharmaceuticals, Johnson & Johnson Vision Care, Inc, Kala Pharmaceuticals, Inc, Novaliq GmbH, Novartis Pharmaceuticals Corporation, Ocular Science, Ocular Therapeutix, Inc, Shenyang Sinqi Pharmaceutical Co, Ltd, Sun Pharmaceutical Industries, Inc, TearLab Corporation, Visus Therapeutics, and Zeiss; is a contracted researcher for Aerie Pharmaceuticals, Inc, and Glaukos Corporation; and has individual stocks or stock options in RxSIGHT.

Eric D. Donnenfeld, MD, is a consultant for Alcon, Allegro Ophthalmics, LLC, Allergan, Avellino, Bausch & Lomb Incorporated, Beaver-Visitec International, BlephEx, CorneaGen, Covalent, Crystilex, Dompé US, Inc, ELT Sight, EyePoint Pharmaceuticals, Foresight Pharmaceuticals, Glaukos Corporation, Ivantis Inc, Johnson & Johnson Vision Care, Inc, Kala Pharmaceuticals, Katena Products, Inc, LacriPen/LacriSciences LLP, LayerBio, Inc, LensGen, Mati Therapeutics, Inc, Melt Pharmaceuticals, Mimetogen Pharmaceuticals, Nanowafer, Nova Bay Pharmaceuticals, Inc, Novaliq GmbH, Novartis Pharmaceuticals Corporation, OcuHub LLC, Oculis, Odyssey Medical, Inc, Omega Ophthalmics, Omeros Corporation, Oyster Point Pharma, Inc, Pfizer Inc, PogoTec, PRN, Rapid Pathogen Screening, Inc, Rayner Intraocular Lenses Limited, Regener-Eyes, ReTEAR, Inc, Santen Inc, Strathspey Crown, Sun Pharmaceutical Industries, Inc, Surface Pharmaceuticals Inc, Tarsus Pharmaceuticals, Inc, TearLab Corporation, TearScience, Thea Pharmaceuticals Limited, Veracity Innovations LLC, Versant Ventures, Visionary Ventures, Visus Therapeutics, and Zeiss; and has individual stocks or stock options in Avedro, Inc, CorneaGen, Covalent, Crystilex, ELT Sight, EyePoint Pharmaceuticals, Glaukos Corporation, Ivantis Inc, LacriPen/LacriSciences LLP, LayerBio, Inc, LensGen, Mati Pharmaceuticals, Inc, Melt Pharmaceuticals, Mimetogen Pharmaceuticals, Nova Bay Pharmaceuticals, Inc, OcuHub LLC, Oculis, Orasis Pharmaceuticals, PogoTec, Rapid Pathogen Screening, Inc, Rayner Intraocular Lenses Limited, Regener-Eyes, ReTEAR, Inc, Strathspey Crown, Surface Pharmaceuticals Inc, Tarsus Pharmaceuticals, Inc, TearLab Coropration, Veracity Innovations LLC, Versant Ventures, Visionary Ventures, and Visus Therapeutics.

Alice T. Epitropoulos, MD, is a consultant for Abbott Medical Optics, AbbVie Inc, Alcon, Allergan, Bausch & Lomb Incorporated, Bio-Tissue, Bruder Healthcare, Dompé US, Inc, EyePoint Pharmaceuticals, Eyevance, Imprimis Pharmaceuticals, Inc, Johnson & Johnson Vision Care, Inc, Kala Pharmaceuticals, Novartis Pharmaceuticals Corporation, Ocular Therapeutix, Inc, Oyster Point Pharma, Inc, Physician Recommended Nutriceuticals, Sight Sciences, Sun Pharmaceutical Industries, Inc, Tarsus Pharmaceuticals, Inc, TearScience, Visus Therapeutics, and Zeiss; is on the speakers bureau for Abbott Medical Optics, AbbVie Inc, Alcon, Allergan, Bausch & Lomb Incorporated, Dompé US, Inc, Eyevance, Johnson & Johnson Vision Care, Inc, Kala Pharmaceuticals, Novartis Pharmaceuticals Corporation, Ocular Therapeutix, Inc, Physician Recommended Nutriceuticals, Sun Pharmaceutical Industries, Inc, Tarsus Pharmaceuticals, Inc, and TearScience; is a contracted researcher for Bausch & Lomb Incorporated; and holds a patent with Hilco Vision.

Marguerite B. McDonald, MD, is a consultant for Akorn, Inc, Alcon, Allergan, Bausch & Lomb Incorporated, Dompé US, Inc, Johnson & Johnson Vision Care, Inc, Novartis Pharmaceuticals Corporation, OCULUS, Inc, OCuSOFT Inc, Orca Surgical, Oyster Point Pharma, Inc, Santen Inc, Strōma Medical Corporation, and Sun Pharmaceutical Industries, Inc; and has individual stocks or stock options in Ocuphire Pharma.

Peer Reviewer

This activity was peer reviewed. The peer reviewer has no relevant commercial relationships to disclose.

Planners, Managers, and Writers

MedEdicus planners, managers, and writers have no relevant commercial relationships to disclose.

Accreditation Statement

MedEdicus LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation Statement

MedEdicus LLC designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Commercial Support

This continuing medical education activity is supported through an educational grant from Bausch & Lomb Incorporated.

Off-Label Discussion

This educational activity may include discussion of unlabeled and/or investigational uses of drugs and devices. Please refer to the official prescribing information for each drug or device discussed in this activity for approved dosing, indications, and warnings.

Provider Contact Information

For questions about this educational activity, please contact MedEdicus LLC at info@mededicus.com.

Disclaimer

The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of MedEdicus LLC or Bausch & Lomb Incorporated.

©2022 MedEdicus LLC. 277.1

Available Credit

  • 1.50 AMA PRA Category 1 Credit™
  • 1.50 Participation

Price

Cost:
$0.00
Please login or register to take this course.

Click Take course to proceed to the evaluation and to obtain your certificate.